Immune Effector Cells

Cancer Immunotherapy Guidelines (SITC)
Description: SITC Cancer Immunotherapy Guidelines (CIGs) are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients. Guidelines relating to hematologic malignancies will be published soon.

FACT Immune Effector Cell Inspection and Accreditation Workshop (FACT), December 8, 2017
Description: This training workshop is designed to educate participants on two key perspectives: building quality into their immune effector cell programs and performing peer-based inspections. FACT’s mission is to improve the quality of cellular therapy programs and depends on volunteer experts to visit programs and assess their compliance with the Standards. This peer-review approach keeps FACT accreditation credible, relevant, and useful. Attendees will learn about the mission of FACT, principles of FACT Standards, the accreditation process, and basic inspection techniques.
Registration is free for current inspectors and approved inspector trainees. Physicians wishing to train to become an inspector for the FACT Immune Effector Cell Accreditation Program must meet prerequisite education and experience requirements, submit a satisfactory inspector application, attend an in-person training workshop, view online videos, and complete a test on the requirements. To apply to become an inspector, submit an online application.

FACT Immune Effector Cell Inspection and Accreditation Workshop (FACT), November 9, 2017
Description: This training workshop is designed to educate participants on two key perspectives: building quality into their immune effector cell programs and performing peer-based inspections. FACT’s mission is to improve the quality of cellular therapy programs and depends on volunteer experts to visit programs and assess their compliance with the Standards. This peer-review approach keeps FACT accreditation credible, relevant, and useful. Attendees will learn about the mission of FACT, principles of FACT Standards, the accreditation process, and basic inspection techniques.
Registration is free for current inspectors and approved inspector trainees. Physicians wishing to train to become an inspector for the FACT Immune Effector Cell Accreditation Program must meet prerequisite education and experience requirements, submit a satisfactory inspector application, attend an in-person training workshop, view online videos, and complete a test on the requirements. To apply to become an inspector, submit an online application.

Cytokine Release Syndrome Webinar (ASGCT), June 28, 2017
Description: Marco Davila, MD, PhD, of the H. Lee Moffitt Cancer Center and Research Institute, and Marcela Maus, MD, PhD, of the Massachusetts General Hospital Cancer Center and Harvard University, explain the diagnostic criteria, various grading schemes, the major medical interventions available, and the risks of cytokine release syndrome.

Expanded Use of Donor Lymphocyte Infusion (DLI) On-Demand eCast (AABB Center for Cellular Therapies), March 30, 2017-March 30, 2019
Description: Donor lymphocyte infusion (DLI) was primarily used to treat and prevent relapse. More recently, DLIs are increasingly being used in both myeloablative and non-myeloablative stem cell transplantation to establish full donor chimerism and to treat and prevent infections. Moreover, DLI was typically administered as a single, large dose of lymphocytes (called a bulk dose regimen of ~2x108 CD3 cells); however, recent practices support lower doses to reduce incidences of GVHD. The doses suggested for modulating engraftment and preventing infections also tend to be lower. Thus, many centers have begun to transfuse donor lymphocytes in multiple aliquots, starting at low CD3 cell numbers and escalating the dosage at variable intervals as required (105, 106 vs. 107 CD3 cells per kg, Blood, 2000, 95:67). These changes have resulted in inconsistent and highly variable practices among transplant physicians within our institution with regard to both the number and size of requested cryopreserved doses. The resultant increases in the numbers of doses being cryopreserved (often more than 10 aliquots per patient), if not utilized, have the potential to unnecessarily increase the cost of long term storage of DLI products.

SITC 31st Annual Meeting (SITC), November 9-13, 2016 
Description: Join SITC for the 31st Annual Meeting & Associated Programs November 9-13, 2016 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. Known as the premier destination for scientific exchange, education and networking in the cancer immunotherapy field, this is the conference you don't want to miss!

SITC 2015 30th Anniversary Annual Meeting & Associated Programs Adoptive Immunotherapy Sessions (SITC)

Personalized Drugs of the Future: Engineering Apheresis-Derived T Cells to Treat Cancer (ASFA), January 2015
Description: The learning objectives of this webinar are determining the difference between “cell processing” and “cell engineering”; understanding the future role of apheresis practitioners in the burgeoning field of personalized medicine; explaining what are chimeric antigen receptor T cells and how will they revolutionize the field of cancer immunotherapy.

Dendritic Cell Vaccines for Prostate Cancer  (ASFA), January 2013
Description: This webinar reviews processes including Dendreon scheduling, collection and shipping requirements, and Mayo collection and infusion processes; reviews the evidence supporting Provenge for minimally symptomatic, metastatic, castration resistant prostate cancer; and reviews common toxicities and their management.